,
Byman, Elin
Nägga, Katarina
Gustavsson, Anna-Märta
Andersson-Assarsson, Johanna
Hansson, Oskar
Sonestedt, Emily
Wennström, Malin http://orcid.org/0000-0002-9957-1801
Funding for this research was provided by:
Vetenskapsrådet (201802564)
Crafoordska Stiftelsen (20190508)
Greta och Johan Kocks stiftelser
Demensförbundet
Article History
Received: 1 September 2020
Accepted: 11 November 2020
First Online: 21 November 2020
Ethics approval and consent to participate
: The Regional ethical committee in Lund originally approved the Malmö Diet and Cancer Study (LU 51–90) and later in several stages (2002, Dnr 244-02; 2004, Dnr 154-2004; 2009, Dnr 633-2009; 2011, Dnr 83-2011; and 2013, Dnr 489-2013.) All MDCS participants provided informed consent at the study entry, when no cognitive disorder was present/diagnosed. Samples in cohort 2 were collected with written informed consent for the use of brain tissue and clinical data for research purposes was obtained from all patients or their next of kin in accordance with the International Declaration of Helsinki. Medical ethical evaluation committee of VU Medical Centre, Amsterdam, has approved the procedures of brain tissue collection, and the regional ethical review board in Lund has approved the study (Dnr 2016/155, Dnr 2017/10).
: Not applicable.
: Oskar Hansson has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen, Roche, and Fujirebio. The other authors have no conflict of interest to report.